Omeros Corporation (OMER) Stock

Omeros Corporation operates as a biopharmaceutical company at the forefront of discovering, developing, and commercializing small-molecule and protein-based therapeutics. Specializing in orphan indications and diseases linked to inflammation, complement-mediated disorders, dysfunctional immune systems in cancers, and addictive and compulsive disorders, Omeros focuses on addressing significant unmet medical needs.

Key clinical programs at Omeros include Narsoplimab (OMS721/MASP-2), which has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA) and is currently in Phase III trials for immunoglobulin A nephropathy (IgAN) and atypical hemolytic uremic syndrome (aHUS). Additionally, Narsoplimab is undergoing Phase II trials for the treatment of COVID-19, showcasing its versatility in combating various conditions.

The company's diverse pipeline includes PPAR? (OMS405) in Phase II for opioid and nicotine addiction, and PDE7 (OMS527) in Phase I for addiction, compulsive disorders, and movement disorders. Omeros also advances MASP-3 (OMS906) in Phase I trials for paroxysmal nocturnal hemoglobinuria (PNH) and other disorders related to the alternative pathway.

In preclinical stages, Omeros is developing MASP-2 small-molecule inhibitors for aHUS, IgAN, HSCT-TMA, and age-related macular degeneration. The company is also exploring longer-acting second-generation antibodies targeting MASP-2 and MASP-3 small-molecule inhibitors for PNH and alternative pathway disorders. Moreover, Omeros is engaged in developing GPR174 Inhibitors, Chimeric Antigen Receptor (CAR) T-Cell, and Adoptive T-Cell Therapies for various cancers, alongside G protein-coupled receptor targets for a broad spectrum of disorders.

Founded in 1994 and headquartered in Seattle, Washington, Omeros Corporation continues to expand its innovative research and development efforts, positioning itself as a leader in advancing therapies for complex and underserved medical conditions worldwide.